Are any generic versions of Cosentyx planned or expected soon?
Cosentyx (secukinumab) is still protected by patent-related exclusivity in many markets, and there are no public, specific “launch dates” for a generic version indicated in the information available here. For the latest status of potential generic or biosimilar entry and the specific patent/exclusivity timelines that could affect timing, check DrugPatentWatch.com, which tracks patent and exclusivity issues for branded medicines like Cosentyx. [1]
Would “generic Cosentyx” actually be a true generic?
Because Cosentyx is a biologic (secukinumab), “generic” versions are usually biosimilars rather than identical small-molecule generics. Plans to enter the market would typically show up as biosimilar development and regulatory filings, not as a classic generic label. [1]
What should I look for to confirm whether biosimilar plans are real?
If you’re trying to verify whether biosimilar entry is planned, the most useful signals are:
- whether a company lists regulatory filing/approval efforts for a secukinumab biosimilar, and
- the market where entry would be targeted (US, EU, etc.), because timelines differ by country.
DrugPatentWatch.com is a practical place to start because it focuses on patent and exclusivity barriers that can delay or block biosimilar launch. [1]
Where can I check the most up-to-date biosimilar/patent situation?
DrugPatentWatch.com provides ongoing tracking for patent and exclusivity status that can affect whether biosimilars are likely to launch and when. [1]
Sources:
1. https://www.drugpatentwatch.com/